Friday, May 19, 2017

LOS ANGELES – (May  18, 2017) – LA BioMed and UCLA announced today that they have sold their royalty rights to Kybella®, the first and only FDA-approved injectable drug to treat submental fullness, that was originally developed by LA BioMed and UCLA researchers.

Allergan, a global pharmaceutical company, is marketing Kybella® for the treatment of submental fullness.

Friday, March 31, 2017

LA BioMed Researcher Honored for Outstanding Work in Liver Disease

The Research Society on Alcoholism (RSA), an organization of researchers who specialize in the study of alcoholism, will honor Samuel W. French, MD, a lead researcher at LA BioMed, with its prestigious 2017 Lifetime Achievement Award for his outstanding work in the field of alcohol research at the organization’s annual scientific meeting in Denver on June 28.

Wednesday, February 22, 2017

March 9 event features presentations of the latest in breakthrough technologies

On March  9, LA BioMed will host its Fourth Annual Innovation Showcase featuring a full day of break-through technology presentations and speakers that will address issues surrounding the commercialization of technologies.

The showcase at the Manhattan Beach Marriott is expected to attract more than 300 entrepreneurs, investors, executives from biotech and pharma medical devices companies, legal experts, service providers, prominent scientists and technology transfer

Tuesday, February 21, 2017

LA BioMed among the institutions that participated in extensive studies of testosterone treatments

Research published today found testosterone treatment improved bone density and anemia for men over 65 with low testosterone. But the treatment didn’t improve patients’ cognitive function, and it increased the amount of plaque buildup in participants’ coronary arteries, according to four studies published in the Journal of the American Medical Association (JAMA) and JAMA Internal Medicine.

Tuesday, February 21, 2017

New JAMA Study Finds an Increase in Arterial Plaque

A new study suggests testosterone treatments may increase the risk of heart disease in older men. It found a 20% increase in arterial plaque among men aged 65 and older who received testosterone replacement therapy for a year, according to the study published today in the Journal of the American Medical Association (JAMA).

Wednesday, December 28, 2016

 

Intensive Care Units (ICUs), which provide the most expensive and invasive forms of care in a hospital setting, are being used too often for patients who don’t need that level of care, according to a new study by LA BioMed and UCLA researchers published in the Journal of the American Medical Association Internal Medicine today.

The researchers studied 808 ICU admissions from July 1, 2015 to June 15, 2016 at Harbor-UCLA Medical Center and found that more than half the patients could have been cared for in less expensive and invasive settings.

Monday, November 14, 2016

Study finds low-cost eye drops equal in effectiveness to more costly antibiotics

Bacterial keratitis, an infection of the cornea often caused by contact lenses, malnutrition, or an injury, can lead to corneal scarring, one of the leading causes of blindness around the globe, according to the World Health Organization. It has blinded more than 400,000 children worldwide.

Wednesday, November 2, 2016

Nov. 15 Event to Honor Outstanding Physician-Researchers

In a continuation of a tradition for recognizing its most outstanding physician-researchers, LA BioMed will celebrate the many accomplishments of Drs. Sherwin J. Isenberg, Nora C.J. Sun and Ronald S. Swerdloff on Nov. 15 at Legends 2016 at the Torrance Marriott Redondo Beach.  

Thursday, October 27, 2016

Study addresses long-standing question for those with moderately low blood oxygen levels

Newly published data from the Long-Term Oxygen Treatment Trial (LOTT) show that oxygen use is not beneficial for most people with chronic obstructive pulmonary disease (COPD) and moderately low levels of blood oxygen.

Monday, October 10, 2016

Researchers find Divergent Views on Barriers to Diabetic Retinopathy Screening

LOS ANGELES – (Oct. 10, 2016) – While diabetes is the most common cause of blindness in the working-age population in the U.S., only about 55% of lower income adults living with the disease undergo the retinal screening needed to detect and help prevent blindness.